HT Capital Limited (HTC) is an independent private equity firm based in Hong Kong, founded in 2013, that adopts a value-add and opportunistic investment approach targeting property development projects, established and growth-oriented businesses across real estate, education, hospitality, biotech, and technology sectors.
33% of their portfolio is in Biotech & Life Sciences. Average disclosed round size is $45.1M (across 6 rounds with reported amounts).
Portfolio
6
Fund Size
—
Top Stage
Series A
Last 12 Mo
0
Portfolio Breakdown
Stage Distribution
Investment Activity
DealsAvg Round Size
Portfolio
6 investments
| Company | Round | Amount | Date |
|---|---|---|---|
 Triarm Therapeutics | Unknown | $60M | Sep 2021 |
 Alebund | Series B | $54.5M | Sep 2021 |
| LLumus | Series C | $45M | Dec 2016 |
| SSteel Wool Studios | Series A | $5M | Aug 2016 |
| RRadd3 | Series A | $2.2M | Jul 2016 |
| KKKBOX | Series D | $104M | Aug 2014 |
Top Co-Investors
KDDI1 shared
Shanda Group1 shared
Presence Capital1 shared
Sherpa Healthcare Partners1 shared
Loyal Valley Capital1 shared
3E Bioventures Capital1 shared
Quan Funds1 shared
Morningside1 shared
YuanBio Venture Capital1 shared
Panacea Venture1 shared
Last updated: 8 September 2026